Initiatives aim to spur development of drugs for rare diseases

04/25/2011 | Google

Several initiatives are encouraging pharmaceutical companies to bolster development of drugs for rare and neglected medical conditions. The NIH is set to launch in the fall a scientific center to transform genetic discoveries into therapies, while the International Rare Diseases Research Consortium is aiming for at least 200 more orphan drugs by 2020. Furthermore, senators introduced a bipartisan bill that would give drugmakers an incentive to developing treatments for children with rare diseases.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC